Aurdan Capital Management’s Quest Diagnostics DGX Stock Holding History

Aurdan Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$317K	Sell	1,496 -227	-13%	-$44.6K	0.08%	80
2026 Q1	$338K	Sell	1,723 -714	-29%	-$139K	0.1%	72
2025 Q4	$423K	Sell	2,437 -354	-13%	-$64.5K	0.13%	68
2025 Q3	$532K	Sell	2,791 -4,146	-60%	-$736K	0.17%	59
2025 Q2	$1.25M	Sell	6,937 -660	-9%	-$115K	0.42%	42
2025 Q1	$1.29M	Buy	+7,597	New	+$1.25M	0.48%	39

Other funds holding DGX

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Aurdan Capital Management's DGX Position: Q2 2026 in Review

Aurdan Capital Management reduced its Quest Diagnostics (DGX) stake by 13% in Q2 2026, selling an estimated $44.6K and leaving 1,496 shares worth $317K. The position accounts for 0.08% of the portfolio, ranked #80.

Aurdan Capital Management first reported a position in DGX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.29M in Q1 2025. 444 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Aurdan Capital Management held 1,496 shares of Quest Diagnostics worth $317K as of Q2 2026.
Aurdan Capital Management sold 227 Quest Diagnostics shares in Q2 2026, an estimated $44.6K.
Quest Diagnostics made up 0.08% of Aurdan Capital Management's portfolio in Q2 2026, its #80 holding.
Aurdan Capital Management first reported a position in Quest Diagnostics in Q1 2025 and has held it in 6 quarters since.
Aurdan Capital Management's Quest Diagnostics position peaked at $1.29M in Q1 2025.
444 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Aurdan Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.